Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ANIP stock, giving a Buy rating on July 24.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Faisal Khurshid’s rating is based on the belief that ANI Pharmaceuticals’ fundamental outlook remains strong despite the recent court ruling in favor of CGON. The outcome of the trial, which involved a dispute over royalties related to a bladder cancer drug, was not considered a critical factor in the investment thesis for ANIP. Khurshid emphasizes that the company’s growth prospects, particularly through its Cortrophin Gel product, continue to be a central focus for future performance.
Furthermore, Khurshid anticipates that the upcoming earnings report in the second quarter of 2025 will be a significant event for the company’s stock. The expectation is for consistent growth across ANI Pharmaceuticals’ various business segments. Despite the legal setback, the analyst maintains a positive outlook on the company’s business model and potential for appreciation, reiterating the Buy rating.
According to TipRanks, Khurshid is a 5-star analyst with an average return of 26.7% and a 54.17% success rate. Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Spyre Therapeutics, and Rhythm Pharmaceuticals.
In another report released on July 24, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $75.00 price target.